CV
Univ. Prof. Dr. med. Martin L. Sos
Academic education
2000 - 2007: Medical School, University of Cologne
Scientific degrees
12/2007: MD (summa cum laude), Medical Faculty, University of Cologne, Supervisor Prof. Dr. Jürgen Wolf
06/2007: Graduation from Medical School, University of Cologne
Scientific career
2015 - present: Professor for Molecular Pathology, Institute of Pathology & Department of Translational Genomics, University of Cologne
2014 - 2015: Junior Group Leader, Department of Translational Genomics, University of Cologne
2012 - 2014: Postdoctoral Fellow, Shokat Lab, Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, USA
2010 - 2012: Clinical Research fellow at the Center of Integrated Oncology, Lung Cancer Group Cologne, University of Cologne
2007 - 2010: Postdoctoral Fellow, Thomas Lab, Max-Planck Institute for Neurological Research, Cologne
Honors/ Awards/ Memberships
2016 - 2019: present Speaker of NRW-funded research consortium within the EFRE call (EMODI)
2014 - 2018: Speaker of BMBF-funded research consortium within the e:Med call (MILES)2012 - 2014 Young Investigator Award, Prostate Cancer Foundation (PCF) USA
2013: Scholar-in-Training Award, AACR - Aflac
2011 - 2013: Young Investigator Award, International Association for the Study of Lung Cancer (IASLC)
2010 - 2011: Scholar-in-Training Award, AACR - Pezcoller Foundation
2009: Scholar-in-Training Award, American Association for Cancer Research (AACR)
2008: Award for outstanding medical thesis, German Association of Hematology and Oncology (DGHO)
2007 - 2008: Young Investigator Fellowship, Max-Planck Institute for Neurological Research, Cologne, Germany
2005 - 2007: Köln Fortune Fellowship, University of Cologne, Germany
Patents
- P2126 PCT S3: A method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to dasatinib
- US Patent 13/371,399: A method of treating lung cancer
- US provisional Patent No. 61/530,847 and 61/606,296: Novel Chemotherapeutics
Contact Information
Univ. Prof. Dr. med. Martin L. Sos
Professor (W2)
University Hospital of Cologne, University of Cologne
Molecular Pathology, Institute for Pathology
Department of Translational Genomics
10 most relevant publications
- Mueller S, de Andrade Krätzig N, Tschurtschenthaler M, Silva MG, Thordsen C, Trozzo R, Simon P, Saab F, Kaltenbacher T, Zukowska M, Lucarelli D, Öllinger R, Griger J, Groß N, Groll T, Löprich J, Zaurito AE, Schömig LR, Bugter JM, Bärthel S, Falcomatà C, Strong A, Brandt C, Najajreh M, Papargyriou A, Maresch R, Collins KAN, Sailer D, Schneeweis C, Burger S, Fröhlich LM, Klement C, Belka A, Montero JJ, Jungwirth U, Reichert M, Moser M, Neumann J, Vassiliou G, Cadiñanos J, Varela I, Marr C, Alonso DF, Lollini PL, Zhao J, Chesler L, Isacke CM, Riedel A, Braun CJ, Sos ML, Beleggia F, Reinhardt HC, Musteanu M, Barbacid M, Quante M, Schmidt-Supprian M, Schneider G, Clare S, Lawley TD, Dougan G, Steiger K, Conte N, Bradley A, Rad L, Saur D, Rad R. A disease model resource reveals core principles of tissue-specific cancer evolution. Nature. 2026;653(8113):265-276. doi:10.1038/s41586-026-10187-2
- Samarin J, Nůsková H, Fabrowski P, Malz M, Amtmann E, Taeubert MJ, Pastor-Flores D, Kazdal D, Kurilov R, de Vries N, Pink H, Deis F, Hummel-Eisenbeiss J, Renz L, Kaushal K, Morgen M, Dick TP, Hamilton G, Muckenthaler M, Mall M, Lim B, Kanamaru T, Klinke G, Sos ML, Frede J, Miller AK, Alborzinia H, Gunkel N. Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy. Nat Commun. 2026;17(1):3435. doi:10.1038/s41467-026-71608-4
- Sakthivelu V, Schmitt A, Odenthal F, Ndoci K, Touet M, Shaib AH, Chihab A, Wani GA, Nieper P, Hartmann GG, Pintelon I, Kisis I, Boecker M, Eckert NM, Iannicelli Caiaffa M, Ibruli O, Weber J, Maresch R, Bebber CM, Chitsaz A, Lütz A, Kim Alves Carpinteiro M, Morris KM, Franchino CA, Benz J, Pérez-Revuelta L, Soriano-Campos JA, Huetzen MA, Goergens J, Jevtic M, Jahn-Kelleter HM, Zempel H, Placzek A, Hennrich AA, Conzelmann KK, Tumbrink HL, Hunold P, Isensee J, Werr L, Gaedke F, Schauss A, Minère M, Müller M, Fenselau H, Liu Y, Heimsoeth A, Gülcüler Balta GS, Walczak H, Frezza C, Jachimowicz RD, George J, Schmiel M, Brägelmann J, Hucho T, von Karstedt S, Peifer M, Annibaldi A, Hänsel-Hertsch R, Persigehl T, Grüll H, Sos ML, Reifenberger G, Fischer M, Adriaensen D, Büttner R, Sage J, Brouns I, Rad R, Thomas RK, Anstötz M, Rizzoli SO, Bergami M, Motori E, Reinhardt HC, Beleggia F. Functional synapses between neurons and small cell lung cancer. Nature. 2025;646(8087):1243-1253. doi:10.1038/s41586-025-09434-9
- Valdez Capuccino L, Kleitke T, Szokol B, Svajda L, Martin F, Bonechi F, Krekó M, Azami S, Montinaro A, Wang Y, Nikolov V, Kaiser L, Bonasera D, Saggau J, Scholz T, Schmitt A, Beleggia F, Reinhardt HC, George J, Liccardi G, Walczak H, Tóvári J, Brägelmann J, Montero J, Sos ML, Őrfi L, Peltzer N. CDK9 inhibition as an effective therapy for small cell lung cancer. Cell Death Dis. 2024;15(5):345. doi:10.1038/s41419-024-06724-4
- Müller N, Lorenz C, Ostendorp J, Heisel FS, Friese UP, Cartolano M, Plenker D, Tumbrink H, Heimsoeth A, Baedeker P, Weiss J, Ortiz-Cuaran S, Büttner R, Peifer M, Thomas RK, Sos ML*, Berg J*, Brägelmann J*. Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer. Cancer Res. 2023;83(15):2471-2479. doi:10.1158/0008-5472.CAN-22-2605 *co-senior and corresponding authors
- Brägelmann J, Lorenz C, Borchmann S, Nishii K, Wegner J, Meder L, Ostendorp J, Ast DF, Heimsoeth A, Nakasuka T, Hirabae A, Okawa S, Dammert MA, Plenker D, Klein S, Lohneis P, Gu J, Godfrey LK, Forster J, Trajkovic-Arsic M, Zillinger T, Haarmann M, Quaas A, Lennartz S, Schmiel M, D’Rozario J, Thomas ES, Li H, Schmitt CA, George J, Thomas RK, von Karstedt S, Hartmann G, Büttner R, Ullrich RT, Siveke JT, Ohashi K, Schlee M, Sos ML. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nat Commun. 2021;12(1):5505. doi:10.1038/s41467-021-25728-8
- Bebber CM, Thomas ES, Stroh J, Chen Z, Androulidaki A, Schmitt A, Höhne MN, Stüker L, de Pádua Alves C, Khonsari A, Dammert MA, Parmaksiz F, Tumbrink HL, Beleggia F, Sos ML, Riemer J, George J, Brodesser S, Thomas RK, Reinhardt HC, von Karstedt S. Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. Nat Commun. 2021;12(1):2048. doi:10.1038/s41467-021-22336-4
- Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Büttner R, Sen T, Byers LA, Reinhardt HC, Letai A, Oliver TG, Sos ML. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nat Commun. 2019;10(1):3485. doi:10.1038/s41467-019-11371-x
- Fassunke J, Müller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Heimsoeth A, Dahmen I, Fischer RN, Scheffler M, Ihle MA, Priesner V, Scheel AH, Wagener S, Kron A, Frank K, Garbert K, Persigehl T, Püsken M, Haneder S, Schaaf B, Rodermann E, Engel-Riedel W, Felip E, Smit EF, Merkelbach-Bruse S, Reinhardt HC, Kast SM, Wolf J, Rauh D, Büttner R, Sos ML. Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nat Commun. 2018;9(1):4655. doi:10.1038/s41467-018-07078-0
- Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, Varga Z, Balke-Want H, French CA, Peifer M, Reinhardt HC, Örfi L, Kéri G, Ansén S, Heukamp LC, Büttner R, Rauh D, Klebl BM, Thomas RK, Sos ML. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Rep. 2017;20(12):2833-2845. doi:10.1016/j.celrep.2017.08.082
